Cambridge Antibody Technology

Cambridge Antibody Technology (CAT) was a biotechnology company specializing in creating synthetic antibodies used for medical treatments. Antibodies are proteins that recognize and bind to specific targets, such as diseases. CAT developed innovative techniques to rapidly design and produce these antibodies, improving drug development. Their work contributed to advances in therapies for cancer, autoimmune diseases, and other conditions. In 2007, CAT was acquired by AstraZeneca, integrating its technologies into larger drug development efforts. Overall, CAT played a significant role in advancing antibody-based medicines, making treatments more targeted and effective.